Which pharmaceutical company manufactures Erdafitinib?

Erdafitinib (Erdafitinib) is an innovative targeted drug developed and produced by Janssen Pharmaceuticals, a subsidiary of the world-renowned pharmaceutical company Johnson & Johnson. As an important subsidiary of Johnson & Johnson, Janssen has long been focused on research and development in the fields of oncology, immunology, infectious diseases, and neuroscience, and has accumulated rich research and development experience in oncology, especially precision treatment. The advent of erdafitinib is one of the important achievements of Janssen’s strategic layout of molecular targeted therapy.

As the first FGFR inhibitor approved by the U.S.FDA, erdafitinib is a milestone in the history of drug development. As early as the beginning of research and development, scientists have discovered that some bladder cancer patients have FGFR2 or FGFR3 gene abnormalities. However, this subgroup of patients often has poor efficacy and unsatisfactory prognosis in traditional chemotherapy and immunotherapy. The Janssen team invested in research and development against this background, and after multiple rounds of clinical trial verification, it finally promoted the approval of erdafitinib in 2019 for the treatment of patients with locally advanced or metastatic bladder cancer harboring FGFR gene alterations. This not only provides new options for the medical field, but also moves targeted drug therapy from theory to wider clinical application.

Currently, erdafitinib has been approved for marketing in many countries and regions, including the United States, Japan and parts of Europe. The Chinese market has also approved its import and sales in recent years. The design of drug specifications is diversified to meet different dosage requirements. This is a reflection of Janssen's full consideration of patient compliance and clinical practice during the research and development process. At the same time, Janssen is also actively promoting its research in other indications, such as cholangiocarcinoma, breast cancer, etc. These explorations show the potential value of erdafitinib in the treatment of cross-cancer types.

References：https://www.balversa.com/